Study Shows Injecting Monoclonal Antibodies Prevents COVID-19 Infection

A new study published in the New England Journal of Medicine shows that the injection of two monoclonal antibodies—casirivimab and imdevimab—significantly reduces risk of COVID-19 infection among those exposed to the virus. The research included participants who had been exposed to SARS-CoV-2 in their household within the past 96 hours. One group received the monoclonal antibody injection and the control group received a placebo. Those who received the injection were 72% less likely to develop COVID-19 within 1 week; this percentage grew to 93% 1 week after the injection was administered. The study was a randomized, double-blind, placebo-controlled clinical trial, which is at the top of the evidence pyramid. Click here to read more.